InsidersTradesSigma
RemeGen Co., Ltd.: management transactions · Hong Kong · HKEX
HKEX:remegen-co-ltd-h-sharesHK·HKEXMcap 51.1Bn€Healthcare
Browse the full management transaction log of RemeGen Co., Ltd., a listed issuer based in Hong Kong. Shares are listed on HK HK, under the supervision of HKEX. Operating in the Healthcare sector, RemeGen Co., Ltd. has published 53 reports. Market capitalisation: €51.1bn. The latest transaction was disclosed on 24 April 2026 — Sale. Among the most active insiders: Lin Jian. The full history is free.
53
Insider Decl.
0
Thresholds
·
0 ops.
Buy Volume
€37m
53 ops.
Sell Volume
Financial data
FY ended December 2025 · cache
85.80 €
Analyst consensus
15 analystsBuy
76.06 €Target 116.27 €(+36%)144.27 €
Income statement
Revenue3.24 Bn€
Gross profit2.82 Bn€87% margin
Net income709.6 M€38.2% margin
Valuation
PER (trailing)58.0x
PER (forward)62.5x
P/Book10.7x
Beta0.48
Balance sheet & cash
Market cap51.11 Bn€
Total debt2.20 Bn€
Free Cash Flow−147.7 M€
Debt / Equity53%
Profitability & ownership
ROE45.3%
ROA3.4%
% insiders10.4%
% institutions28.8%
Last declaration on 24 April 2026
Declarations53 total
Executives●Sale7HKEX
€214,71920,000 shares@ €10.73590.0004% mcap2.9% of flow
ShareXHKG
HKEX:DA20260423E00709·
Executives●Sale8HKEX
€531,66453,000 shares@ €10.03140.0010% mcap7.2% of flow
ShareXHKG
HKEX:DA20260423E00712·
Executives●Sale8HKEX
€679,37460,000 shares@ €11.32290.0013% mcap9.2% of flow
ShareXHKG
HKEX:DA20260423E00707·
Executives●Sale7HKEX
€99,40710,000 shares@ €9.94070.0002% mcap1.3% of flow
ShareXHKG
HKEX:DA20260423E00706·
Executives●Sale9HKEX
€2m160,000 shares@ €9.88980.0031% mcap21.4% of flow
ShareXHKG
HKEX:DA20260423E00705·
Executives●Sale8HKEX
€573,79760,000 shares@ €9.56330.0011% mcap7.7% of flow
ShareXHKG
HKEX:DA20260423E00704·
Executives●Sale8HKEX
€569,42060,000 shares@ €9.49030.0011% mcap7.7% of flow
ShareXHKG
HKEX:DA20260423E00703·
Executives●Sale9HKEX
€1m100,000 shares@ €11.88260.0023% mcap16.0% of flow
ShareXHKG
HKEX:DA20260423E00701·
Executives●Sale8HKEX
€531,66453,000 shares@ €10.03140.0010% mcap7.2% of flow
ShareXHKG
HKEX:DA20260423E00729·
Executives●Sale7HKEX
€214,71920,000 shares@ €10.73590.0004% mcap2.9% of flow
ShareXHKG
HKEX:DA20260423E00726·
Executives●Sale9HKEX
€2m160,000 shares@ €9.88980.0031% mcap21.4% of flow
ShareXHKG
HKEX:DA20260423E00722·
Executives●Sale8HKEX
€679,37460,000 shares@ €11.32290.0013% mcap9.2% of flow
ShareXHKG
HKEX:DA20260423E00724·
Executives●Sale7HKEX
€99,40710,000 shares@ €9.94070.0002% mcap1.3% of flow
ShareXHKG
HKEX:DA20260423E00723·
Executives●Sale8HKEX
€573,79760,000 shares@ €9.56330.0011% mcap7.7% of flow
ShareXHKG
HKEX:DA20260423E00721·
Executives●Sale8HKEX
€569,42060,000 shares@ €9.49030.0011% mcap7.7% of flow
ShareXHKG
HKEX:DA20260423E00720·
Executives●Sale9HKEX
€1m100,000 shares@ €11.88260.0023% mcap16.0% of flow
ShareXHKG
HKEX:DA20260423E00718·
Executives●Sale8HKEX
€679,37460,000 shares@ €11.32290.0013% mcap9.2% of flow
ShareXHKG
HKEX:DA20260423E00690·
25 of 53 declarations
About RemeGen Co., Ltd.
RemeGen Co., Ltd. is a Chinese biopharmaceutical company focused on the research and development of treatments for cancer and other serious diseases. It is listed on the Hong Kong Stock Exchange under the H Shares symbol.